KRAS IN-44

KRAS IN-44 (Compound S2C2M2) is a PDE6D degrader. KRAS IN-44 inhibits PDE6D-dependent KRAS trafficking and KRAS downstream signaling pathways. KRAS IN-44 down-regulates EGF-induced the phosphorylation of PI3K, AKT, and mTOR. KRAS IN-44 increases Apoptosis. KRAS IN-44 has antitumor activity against hepatoblastoma[1].

Product Specifications

UNSPSC

12352005

Target

Akt; Apoptosis; mTOR; Phosphodiesterase (PDE) ; PI3K; Ras

Related Pathways

Apoptosis; GPCR/G Protein; MAPK/ERK Pathway; Metabolic Enzyme/Protease; PI3K/Akt/mTOR

Field of Research

Cancer

Smiles

ClC1=CC=C([C@@H]2[C@H](C3=CC=C(Cl)C=C3)N(C(N4CC(N(CC(NCCOCCOCCN5C=C(COCC(NC(CCNC(CC[C@@H](C)[C@]6([H])[C@]([C@@H](O)C[C@@]7([H])[C@@]8([H])[C@H](O)C[C@@]9([H])[C@]7(C)CC[C@@H](O)C9)(C)[C@@]8([H])CC6)=O)=O)C(NCCNC(C%10=NC=CC(OC%11=CC=C(NC(NC%12=CC=C(Cl)C(C(F)(F)F)=C%12)=O)C=C%11)=C%10)=O)=O)N=N5)=O)CC4)=O)=O)C(C%13=CC=C(OC)C=C%13OC(C)C)=N2)C=C1

Molecular Formula

C93H113Cl3F3N15O17

Molecular Weight

1876.34

References & Citations

[1]Liang J, et al. An NTCP-mediated liver-targeting chimeras (NTLiverTac) design strategy and its application to hepatoblastoma models. Bioorg Chem. 2025 Jul 15;162:108622.